Toyocamycin

4-Amino-5-cyano-7-(D-ribofuranosyl)-7H- pyrrolo(2,3-d)pyrimidine. Antibiotic antimetabolite isolated from Streptomyces toyocaensis cultures. It is an analog of adenosine, blocks RNA synthesis and ribosome function, and is used mainly as a tool in biochemistry.

Also Known As:

Networked: 28 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Akazawa, Yuko: 2 articles (01/2020 - 01/2017)
2.	Eguchi, Susumu: 2 articles (01/2020 - 01/2017)
3.	Kanda, Yasuko: 2 articles (01/2020 - 01/2017)
4.	Kido, Youko: 2 articles (01/2020 - 01/2017)
5.	Matsuda, Katsuya: 2 articles (01/2020 - 01/2017)
6.	Miyaaki, Hisamitsu: 2 articles (01/2020 - 01/2017)
7.	Nakao, Kazuhiko: 2 articles (01/2020 - 01/2017)
8.	Nakashima, Masahiro: 2 articles (01/2020 - 01/2017)
9.	Ohnita, Ken: 2 articles (01/2020 - 01/2017)
10.	Sakai, Yusuke: 2 articles (01/2020 - 01/2017)

Related Diseases

1.	Non-alcoholic Fatty Liver Disease 01/01/2017 - "The data we obtained suggest that toyocamycin attenuates hepatocyte lipogenesis and ameliorates NAFLD in vivo and may therefore be beneficial in the treatment of NAFLD in humans." 01/01/2017 - "We also explored the effects of toyocamycin in a mouse model of NAFLD. " 01/01/2020 - "Correction: Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice." 01/01/2017 - "Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice." 01/01/2017 - "In addition, toyocamycin reduced the expression of cytosine-cytosine-adenosine-adenosine-thymidine enhancer-binding protein homologous protein (CHOP), which is a key player in ER stress-mediated apoptosis, as well as its downstream cell death modulator, death receptor 5. In the in vivo study, toyocamycin ameliorated the liver injury caused by FFC-induced NAFLD. "
2.	Prostatic Neoplasms (Prostate Cancer) 02/01/2017 - "We investigated the apoptotic effect of Toyocamycin and the underlying molecular mechanism in prostate cancer PC-3 cells. " 02/01/2017 - "Toyocamycin induces apoptosis via the crosstalk between reactive oxygen species and p38/ERK MAPKs signaling pathway in human prostate cancer PC-3 cells." 01/01/2001 - "When compared to the parent toyocamycin, all these analogues showed much lower cytotoxicity to human prostate cancer cells (HTB-81), mouse melanoma cancer cells (B16) as well as normal human fibroblasts. " 05/01/2006 - "The purpose of the present study was to investigate the mechanisms involved in the antiproliferative and apoptotic effects of MCS-C2, a novel analog of the pyrrolo[2,3-d]pyrimidine nucleoside toyocamycin and sangivamycin, in human prostate cancer LNCaP cells. "
3.	Leukemia 07/01/1982 - "We have previously shown that toyocamycin depresses the production of the Friend leukemia viral complex by chronically infected cells. " 03/01/1970 - "Influence of toyocamycin on avian leukemia myeloblasts: cell growth, ultrastructure, RNA synthesis, and elaboration of BAI strain A virus." 06/08/2005 - "The purpose of the present study was to investigate the anti-proliferative and apoptotic effects of MCS-C2, a novel synthetic analogue of the pyrrolo[2,3-d]pyrimidine nucleoside toyocamycin and sangivamycin, in human promyelocytic leukemia (HL-60) cells. "
4.	Ascites 06/28/1977 - "The present study shows that the antitumor agent toyocamycin (4-amino-5-cyano-7beta-D-ribofuranosylpyrrolo(2-3d)pyrimidine) affects rRNA transcription in Ehrlich ascites cells. " 02/15/1982 - "In BHK21 cells fluorodeoxyuridine has no effect on either rRNA maturation or transcription, whereas toyocamycin (at 2 microM) inhibits both processes in BHK21 cells and Ehrlich ascites cells. "
5.	Neoplasms (Cancer) 07/08/2022 - "Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells." 07/08/2022 - "Altogether, we demonstrated that toyocamycin exhibits specific CDK9 inhibition in cancer cells, highlighting its potential for cancer chemotherapy." 01/01/2023 - "Both in vitro and in vivo results confirm the enhanced cytotoxicity of drug toyocamycin against HeLa cells by peptide assemblies, thus efficiently inhibiting in vivo tumor growth. " 02/01/2017 - "Toyocamycin, an antibiotic agent isolated from Streptomyces species, has been shown to have anticancer and chemopreventive effects on various cancer cells. " 09/01/2014 - "Type-specific inhibition of cancer cell proliferation was observed at micromolar concentrations with the 4-N-(4-nitrobenzyl) derivatives of sangivamycin and toyocamycin, and also with 4-N-benzyltubercidin. "

Related Drugs and Biologics

1.	Nonesterified Fatty Acids (NEFA)
2.	sangivamycin
3.	Nucleosides
4.	MCS-C2
5.	pyrimidine
6.	Adenosine (Adenocard)
7.	TNF-Related Apoptosis-Inducing Ligand Receptors
8.	Thymidine
9.	Proteins (Proteins, Gene)
10.	Cytosine

Related Therapies and Procedures

1.	Precision Medicine
2.	Drug Therapy (Chemotherapy)